Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Clinical Studies
  • View item
  • Home
  • ICR Divisions
  • Clinical Studies
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients.

Thumbnail
View/Open
Supporting information (63.31Kb)
Date
2017-02
ICR Author
Popat, Sanjay
Marsden,
Author
Juan, O
Popat, S
Type
Journal Article
Metadata
Show full item record
URI
https://repository.icr.ac.uk/handle/internal/1161
DOI
https://doi.org/10.1016/j.lungcan.2016.11.007
Collections
  • Clinical Studies
Subject
Humans
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Pyrazoles
Pyridines
Proto-Oncogene Proteins
Protein Kinase Inhibitors
Neoplasm Staging
Treatment Outcome
Protein-Tyrosine Kinases
Genetic Testing
Molecular Targeted Therapy
Biomarkers, Tumor
Crizotinib
Research team
Thoracic Oncology
Language
eng
Date accepted
2016-11-10
License start date
2017-02
Citation
Lung cancer (Amsterdam, Netherlands), 2017, 104 pp. 131 - 133

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.